



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Akira NISHIYAMA et al.

Serial No. 09/990,389

Filed November 23, 2001

: Confirmation No. 2862

: Docket No. 2001_1748A

: Group Art Unit 1626

: Examiner Andrea Souza Small

PHENOXYPROPYLAMINE COMPOUNDS

TECH CENTER 1600/2900

MAR 14 2003

RECEIVED

Beit
3-18-03

RESPONSE

Assistant Commissioner for Patents,
Washington, D.C.

Sir:

This is responsive to the Official Action dated February 12, 2003.

Initially, Applicants wish to express their appreciation to the Examiner for her modification of the restriction requirement which is indicated in the Examiner Interview Summary Record dated March 5, 2003.

In view of the Interview Summary, Applicants have elected a specific compound from among the present compounds, wherein W is void and V is -O-. The specific compound is 1-(4-(3,4-dichlorophenyl)piperidino)-3-(2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo(b)furan-4-yloxy)-2-propanol. See Example 88, on page 184 of the specification. See also compound (88) recited in claim 5. In this compound, R¹ is option (3).

Favorable action on the merits is solicited.

Respectfully submitted,

Akira NISHIYAMA et al.

By: *Warren M. Cheek, Jr.*

Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
March 12, 2003